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Abstract Fabry’s disease is a chromosomal X-linked
inherited disease, which causes a lack of the lysosomal
alpha-galactosidase A enzyme leading to a cellular
accumulation of glycosphingolipids. This accumulation
leads to various clinical disorders, including inner ear
lesions, with sensorineural hearing loss and dizziness.
This article proposes to describe a clinical case of a
patient suﬀering from Fabry’s disease with inner ear
associated problems and to review the literature focusing
on this subject.
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Introduction
Fabry’s disease is a chromosomal X-linked inherited
disorder that causes the lack of a lysosomal hydrolase
(alpha-galactosidase A), leading to an alteration of the
metabolism and a progressive accumulation of glycos-
phingolipids (predominantly the globotriosylcerca-
mides), into the lysosomes of the whole organism’s cells
and into the blood plasma. The oto-rhino-laryngological
area is not spared by this disease, and the majority of
patients develop a progressive and accelerated sensori-
neural hearing loss during adulthood. One third of the
patients may undergo a sudden unilateral sensorineural
hearing loss. In addition, a high incidence of vestibular
disorders with dizziness and chronic instability is also
observed in these patients.
This article describes a case of a patient aﬀected by
Fabry’s disease that included both a progressive bilateral
sensorineural hearing loss and an additional sudden
unilateral hearing loss. The case report is followed by a
review of the literature concerning the neurotological
consequences of Fabry’s disease.
Case report
A 60-years-old Caucasian male patient was positive for
Fabry’s disease and presented the majority of its mani-
festations: acrodynia, acroparesthesia, angiokeratoma,
vasculitis, hypertrophic cardiomyopathy complicated by
an atrio-ventricular blockage (a pace maker was
implanted in January 2003), a discrete mitral insuﬃ-
ciency, and terminal renal insuﬃciency that required a
renal graft in March, 2003. Before transplantation, the
patient was treated with haemodialysis three times per
week since December 2001. The post-transplantation
treatment was realized with an association of Cyclo-
sporine (100 mg-0–75 mg) and Tacrilomus (1 g-0–1 g),
and was no modiﬁed later.
The patient was referred for an audiological consul-
tation in the beginning of April 2003 to evaluate the
necessity of a hearing aid. He complained of a bilateral
progressive hearing loss associated with tinnitus, leading
to social and professional conversational disturbances.
Examination revealed normal tympanic membranes, a
midline Weber test and a positive Rinne´ test on both
sides. Pure-tone and speech audiometry were performed.
There was a moderate sensorineural hearing loss bilat-
erally, with poorer sensitivity on the left side (Fig. 1a).
The pure tone average (PTA) between 0.5–4 kHz was
37 dB HL on the right side and 55 dB HL on the left
side. Speech understanding ability was evaluated with
monosyllabic words and revealed a speech recognition
threshold of 72 dB at the right ear and 100 dB at the left
ear (Fig. 1b). According to these results, the patient has
been rehabilitated stereophonically.
At the beginning of May 2003, the patient experi-
enced a period of fever that lasted for 1 week. He was
bed ridden because of the fever and increased dizziness.
During this period, he did not use his hearing aids. One
F. M. Barras (&) Æ R. Maire
Department of Oto-Rhino-Laryngology and Cervico-Facial





Eur Arch Otorhinolaryngol (2006) 263: 688–691
DOI 10.1007/s00405-006-0023-0
week later, he tried to use his hearing aids and noticed
that he could not hear on the left side. The patient
presented for audiological consultation the 23rd of May
2003. The clinical examination showed a normal
tympanic membrane on both sides. The Weber test
showed a lateralization to the right side, while the Rinne´
was positive on the right side and the stimulus could not
be perceived on the left side. The vestibular examination
yielded the following results: normal function of cranial
nerves (excepted for the VIIIth cranial pair), well-
performed cerebellar tests, normal Romberg and
Unterberger tests, normal smooth pursuit and complete
inhibition of perotatory nystagmus with ocular ﬁxa-
tion. The examination under videoscopy showed no
Fig. 1 Audiological evaluation in April 2003. a Pure tone
audiogram: pure tone average (PTA) between 0.5–4 KHz of
37 dB HL on the right (circle) side and of 55 dB HL on the left
side (cross). b Speech audiogram (monosyllables): speech recogni-
tion threshold of 72 dB on the right ear (circle) and 100 dB at the
left ear (cross)
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spontaneous nystagmus, no positional (-ing) nystagmus,
and no nystagmus after head shaking. However, the
bi-thermal binaural caloric tests showed a complete
areﬂexy on both sides. The examination was completed
with a pure tone audiogram, which conﬁrmed a
complete loss of hearing sensitivity on the left side, with
test results for the right side similar to those obtained in
April 2003 (Fig. 2). The electroacoustic characteristics
of the hearing aid for the right side were adjusted to
reﬂect the change from a binaural to a monaural ﬁtting,
and hearing aid use for the left side was discontinued.
During July 2003, the patient experienced a further
deterioration of the hearing sensitivity on the right ear,
with an additional 20 dB loss at 500 Hz, and 10 dB at
the other frequencies (Fig. 2). A corticotherapy with
1 mg/kg prednisone during 10 days was administered,
but no signiﬁcant recovery was observed.
Audiometric evaluation was preformed at the end of
September 2003, and the hearing sensitivity for the right
ear was unchanged from results obtained on July 2003.
No recovery occurred on the left side. A BICROS sys-
tem with ampliﬁcation of the right ear was proposed to
the patient, but he preferred to retain the monaural
ﬁtting.
Discussion and review of the literature
Fabry’s disease is a rare genetic disorder, with a
frequency of occurrence of 1 in 100,000 births [1]. It is
the second most common glycosphingolipid storage
disorder after Gaucher’s disease. Considering the inner
ear, Fabry’s disease frequently leads to labyrinth
dysfunctions, such as sensorineural hearing loss, sudden
deafness, tinnitus and dizziness or vertigo[2, 3, 4, 5].
A sensorineural hearing loss is the most common man-
ifestation of the disease in the labyrinth. As many as
50–78% of patients aﬀected with Fabry’s disease will
develop auditory symptoms during their life, as observed
in two studies including 22 and 98 patients with Fabry’s
disease, respectively [2, 3]. An increased incidence of
tinnitus and sudden sensorineural hearing loss has also
been reported in Fabry’s disease compared to the nor-
mal population [2]. This situation was encountered in
our patient, who ﬁrst experienced a progressive hearing
loss on both ears, followed by a sudden hearing loss on
the left side.
The causes of hearing loss (progressive or sudden) in
patients aﬀected by Fabry’s disease are still not known.
Some authors postulate that it is not diﬀerent from the
presbycusis present in the normal population [5]. How-
ever, some hypotheses to explain both the progressive
and sudden sensorineural hearing loss have been
reported in the literature: deposition of glycosphingoli-
pids into the inner ear [2], long term obstruction of
cranial vessels by dolicho-ectatic arteries, due to the
local deposition of glycosphingolipids into the wall of
arteries [4]. Postmortem histopathologic examination of
temporal bones of aﬀected patients have shown both
middle and inner ear alterations: seropurulent eﬀusions
Fig. 2 Audiological evaluation
since May 2003. Left ear:
complete deafness, no further
recovery. Right ear: degree of
pure tone thresholds in May
(A), and on retest in July and
September (B)
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and hyperplastic mucosa were found in middle ears;
strial and spiral ligament atrophy, hair cell loss and
reduced number of ﬁbers in spiral ganglia were found in
inner ears; no evidence of glycosphingolipid accumula-
tion was observed in spiral ganglia [6]. Other authors
postulate that the hearing loss could be attributed to
chronic renal insuﬃciency and dialysis, which have been
described as potentially deleterious for the inner ear[7,
8]. Fabry’s disease is also known for its impact on the
balance system, leading to dizziness. The major cause of
dizziness is an alteration of the central balance centers
(cerebellar vermis and vestibular nuclei) occasioned by
focal infarcts due to thrombotic zones into these central
balance centers [4]. However, a peripheral origin can
also be detected with bilateral areﬂexia after caloric
stimulation [2], as found in our patient.
Initial signs of Fabry’s disease can be detected during
infancy. They include angiokeratoma, acroparesthesia,
acrodynia, dysautonomia and corneal opacities. Further
deposition of glycosphingolipids into the endothelial
cells and in the smooth muscle cells of micro-vessels
leads to narrowing and thrombosis of little arteries and
arterioles. These depositions may produce ischemic
cerebral and cardiac complication as well as progressive
renal insuﬃciency, which may lead to premature death.
However, the disease can be recognized during child-
hood by speciﬁc neurological symptoms such as severe
episodes of lancinating pain or burning paresthesia in
the extremities [9]. The early detection of the disease
during infancy is important to initiate treatment as early
as possible. Indeed, enzyme replacement therapy is
emerging as a new treatment, with good results. It allows
the accumulation of glycosphingolipids into the wall of
small arteries to be delayed or even stopped, thus
preventing the life-threatening consequences of the
disease [9, 10, 11, 12].
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